Afatinib (Giotrif®) :
The 1st choice
in 1st-line
Superior efficacy vs gefitinib and vs chemotherapy
demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
RealGiDo - Real-world study on dose adjustment
Document ID: PC-PH-100404
01/11/2018
Author: Boehringer Ingelheim
RealGiDo, a global study across 13 countries, confirmed that dose adjustment is effective to help manage side effects, without compromising efficacy.
Disclaimer: The standard Afatinib (Giotrif®) dose is 40 mg/day.
123,000
Views
100k 340
References & Footnote:
1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.
2. Wu YL et al. Lancet Oncol. 2014;15(2):213-22.
3. Yang JC et al. Lancet Oncol. 2015;16(2):141-51.
4. Park K et al. Abstract LBA2 and oral presentation. European Society for Medical Oncology (ESMO) ASIA, Singapore, 20th December 2015.
EGFR M+=epidermal growth factor receptor mutation positive; NSCLC=non-small cell lung cancer; PFS=progression-free survival; OS=overall survival.
* LUX-Lung 3 (vs pemetrexed/cisplatin) and LUX-Lung 6 (vs gemcitabine/cisplatin): superior PFS (primary endpoint) and superior OS in Del19 subgroup (secondary endpoint); LUX-Lung 7 (vs gefitinib): superior PFS (primary endpoint).
RELATED CONTENT
MPR-PH-100073
Production date: Nov 2018
Production date: Nov 2018
What is Afatinib (Giotrif®)?
Afatinib (Giotrif®) is an irreversible ErbB Family blocker approved in more than 70 markets. It is indicated for the treatment of patients with distinct types of epidermal growth factor receptor EGFR mutation-positive (EFGR M+) locally advanced or metastatic non-small cell lung cancer (NSCLC), and for the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. It is an oral, once-daily, targeted therapy.[1]
*Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name Giotrif®, in the US under the brand name Giotrif® and in India under the brand name Xovoltib®
*Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name Giotrif®, in the US under the brand name Giotrif® and in India under the brand name Xovoltib®
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about Afatinib (Giotrif®)?
The side effects of Afatinib are predictable, generally manageable and reversible. In studies to date, drug-related adverse events (AEs) were largely related to the gastrointestinal tract (diarrhoea) and skin disorders (rash), which is in line with EGFR tyrosine kinase inhibition.[1-4] For further details, please refer to the prescribing information.
References:
[1] GIOTRIF® Summary of Product Characteristics 2018
[2] Sequist L et al. J Clin Oncol 2013;31(27)3327–34.
[3] Wu YL et al. Lancet Oncol 2014;15(2):213–22.
[4] Park K et al. Lancet Oncol 2016;17(5):577–89.
The side effects of Afatinib are predictable, generally manageable and reversible. In studies to date, drug-related adverse events (AEs) were largely related to the gastrointestinal tract (diarrhoea) and skin disorders (rash), which is in line with EGFR tyrosine kinase inhibition.[1-4] For further details, please refer to the prescribing information.
References:
[1] GIOTRIF® Summary of Product Characteristics 2018
[2] Sequist L et al. J Clin Oncol 2013;31(27)3327–34.
[3] Wu YL et al. Lancet Oncol 2014;15(2):213–22.
[4] Park K et al. Lancet Oncol 2016;17(5):577–89.
